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Abstract
Glial activation via Toll-like receptor (TLR) signaling has been shown in animals to play an important role in the initiation and
establishment of chronic pain. However, our ability to assess this central immune reactivity in clinical pain populations is
currently lacking. Peripheral blood mononuclear cells (PBMCs) are an accessible source of TLR expressing cells that may
mirror similarities in TLR responsiveness of the central nervous system. The aim of this study was to characterize the IL-1b
response to various TLR agonists in isolated PBMCs from chronic pain sufferers (on and not on opioids) and pain-free
controls. Venous blood was collected from 11 chronic pain sufferers on opioids ($ 20 mg of morphine / day), 8 chronic pain
sufferers not on opioids and 11 pain-free controls. PBMCs were isolated and stimulated in vitro with a TLR2 (Pam3CSK4),
TLR4 (LPS) or TLR7 (imiquimod) agonist. IL-1b released into the supernatant was measured with ELISA. Significantly
increased IL-1b expression was found in PBMCs from chronic pain sufferers (on and not on opioids) compared with pain-free
controls for TLR2 (F (6, 277) = 15, P,0.0001), TLR4 (F (8, 263) = 3, P= 0.002) and TLR7 (F (2,201) = 5, P= 0.005) agonists. These data
demonstrate that PBMCs from chronic pain sufferers were more responsive to TLR agonists compared with controls,
suggesting peripheral cells may have the potential to become a source of biomarkers for chronic pain.
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Introduction
Traditionally, the mechanisms underlying chronic pain have
thought to be solely neuronally based. However, there is now
overwhelming evidence from animal studies [1,2,3,4,5,6,7,8] that
pro-inflammatory activation of the immune-like cells (glia), found
in the central nervous system (CNS), are central to the initiation
and the progression of chronic pain such as neuropathic pain
[9,10]. Despite this however, there remains a lack of human data
demonstrating that these pathways are relevant to clinical pain.
Toll-like receptors (TLRs) are a key detection system via which
glia become activated and release pro-inflammatory cytokines [8].
TLRs form a key part of the innate immune system, capable of the
detection of ‘‘self’’ molecules known as danger-associated molec-
ular patterns (DAMPs) or ‘‘non-self’’ molecules produced by
microorganisms known as pathogen-associated molecular patterns
(PAMPs). Examples of exogenous TLR agonists include: lipopep-
tides recognized by TLR2 homodimer or by TLR2-TLR1 or
TLR2-TLR6 heterodimers, lipopolysaccharide by TLR4 and
single-stranded viral RNA by TLR 7 [11]. Once TLRs bind
PAMPs, a series of signal transduction cascades occur, leading to
the activation of NF-kB and c-Jun N-terminal kinases (JNKs) [12]
which induce the transcription of genes encoding cytokines and
chemokines that are involved in the initiation of the inflammatory
process [13].
TLRs have been implicated in preclinical models of chronic
pain [8]. Blocking of TLRs, either genetically [14,15], or
pharmacologically [16], has been found to reduce microglial
activation, reduce pro-inflammatory cytokine level and produce a
reduction in experimentally-induced neuropathic pain in animals
[8]. Therefore, the propensity of an individual towards proin-
flammatory TLR signaling could be a critical contributor to
chronic pain states.
Opioids are frequently prescribed for moderate to severe pain
but their efficacy is limited by adverse effects such as tolerance
[17]. Interestingly, it has recently been demonstrated that opioids
such as morphine, are also TLR4 agonists [18,19,20,21] therefore
it can induce central immune signaling events that reduces opioid
analgesia and contribute to hyperalgesia [19,22]. The impact of
opioid exposure on TLR signaling in clinical pain populations is
highly relevant and needs to be examined in this study.
Despite the clear evidence from in vitro and in vivo preclinical
models that glial activation and TLR signaling play a critical role
in chronic pain and opioid responses, determining if the same
occurs in human remains difficult due to the general inaccessibility
of the CNS compartment. Excitingly, given the functional
similarities between TLR signaling of immune cells in the
PLOS ONE | www.plosone.org 1 August 2012 | Volume 7 | Issue 8 | e44232
periphery and in the CNS, we hypothesize that indirect evidence
of activity of the TLR pathways in the CNS may be obtained by
examining the activity of the TLR pathways in the peripheral
immune system. Therefore, the TLR responsivity of peripheral
immune cells from different patient populations where TLR
activity is hypothesized to contribute to the disease state should be
different when compared to healthy controls. Such information
could lead to improve mechanistic understandings of pain and to
the discovery of objective pain biomarkers.
Thus, in this study we have examined in vitro responsiveness to 3
different specific TLR agonists in peripheral blood mononuclear
cells from chronic pain patients maintained on opioids, opioid-free
chronic pain patients and opioid-free healthy controls, to
determine whether chronic pain patients have increased respon-
siveness compared to pain-free controls. Moreover, we sought to
investigate the relationship between response scores obtained from
the cold pain test with IL-1b expression from PBMCs after TLR
agonist stimulation. We hypothesized that chronic pain patients
would show increased responsiveness to TLR agonists and that




This study was conducted at the Pain and Anaesthesia Research
Clinic, Royal Adelaide Hospital, Adelaide, Australia. Ethical
approval was obtained from the Human Research Ethics
Committee of the Royal Adelaide Hospital, Adelaide, South
Australia.
All participants gave written informed consent to participate
after a detailed oral explanation of the study. All participants were
paid $50 for their inconvenience upon completion of the study.
Chronic pain patients were recruited from the general public
through advertisements and from a pain management unit.
Healthy participants were recruited from the Pain and Anaesthesia
Research Clinic’s healthy participant database. Thirty participants
were recruited to the study and assigned into three groups
according to their pain and opioid use status. Groups 1 and 2
consisted of chronic pain sufferers. Participants had to experience
pain at least five days a week and for at least 3 months. There was
no minimum pain score. For Group 1, patients had to be taking
ongoing opioid therapy at a dose equivalent to at least 20 mg of
oral morphine per day (calculated according to a comparative
opioid chart [23]). Group 2 patients were not receiving chronic
opioid therapy. Group 3 was the control group in which
participants had no clinically significant chronic pain and were
not taking opioids or other analgesics.
For all participants the key inclusion criteria were the following:
aged between 18 and 65 years, be in good general health (other
than chronic pain for Groups 1 and 2) without clinically significant
renal, hepatic, cardiac or other diseases. Key exclusion criteria
were: use of any immunosuppressant drugs (e.g. azathioprine);
presence of an active inflammatory process; a clinically significant
infection in the previous 4 weeks; Raynaud’s phenomenon or
disease or any other condition associated with abnormal sensitivity
to cold pain; a positive urine screen for illicit drugs (except for
prescribed opioids), pregnancy and/or lactation, and have a
known history of hepatitis B, C or HIV.
Design
The study was of cross sectional design. The study physician was
aware of the pain and medication status of the participants, but
personnel performing the cold pain tests and laboratory evalua-
tions of immune cell reactivity were blinded to the pain and opioid
status of the participant.
Study schedule
Visit 1. On the first visit, information on pain history and
medication use was recorded. Vital signs were recorded and
participants underwent the cold pain test as previously described
[24] in which cold pain threshold and endurance were assessed.
The temperature of the room was set at 22.5uC at all times.
Briefly, the cold pain test consisted of two temperature-controlled
water baths of 34.5–35.5uC and 0.5–1.5uC. A water pump was
placed in the cold-water container to prevent laminar warming
around the immersed limb. Each participant’s non-dominant
forearm and hand (fingers wide apart) was placed vertically into
the warm water for exactly 2 min so that all participants’ starting
temperature was the same. At 1 min 45 s, a blood pressure cuff
was inflated to a pressure 20 mmHg below the diastolic blood
pressure (to minimize the role of blood flow in determining the
reaction to cold). At exactly 2 min, the forearm was placed into the
cold water bath. The participant’s eyes were covered for the entire
procedure to minimize distraction. Once the arm was immersed in
the cold water bath, participants were asked to indicate when they
first experience pain (cold pain threshold), then asked to leave their
arm submerged until they could no longer endure the pain (cold
pain endurance) with a maximum cut-off time of 3 min. Upon
removal of the arm from the cold water bath, participants were
asked to indicate when the pain ceased. Endpoints were measured
as time (s). Participants performed the cold pain test twice with a
20 min interval and the average was recorded.
Visit 2. On visit 2, information on health status, pain severity
and pain medications were checked and recorded. Five ml of
blood was collected into tubes containing EDTA and was sent for
standard haematologic profile. Twenty-seven ml of blood were
collected into tubes containing EDTA and left at room temper-
ature for 1 h until isolation of peripheral blood mononuclear cells
(PBMCs). PBMCs were isolated using Optiprep (Axis-Shield PoC
AS, Oslo, Norway) as directed by the manufacturer using the
mixer flotation method. Control wells minus the TLR agonist
were also included. Isolated cells were diluted to 16106 cells?ml21
in enriched RPMI 1640 (10% foetal calf serum and 1% penicillin)
and plated into 96 well plates (Nunc, Roskilde, Denmark) (100 ml
per well). After allowing the PBMCs to sit for an hour, a range of
concentrations of agonists were added into the wells in triplicate.
TLR2 agonist: synthetic triacylated lipoprotein: Pam3CSK4 from
13 pg?ml21 to 1 mg?ml21 (Sigma); TLR4 agonist: lipopolysaccha-
ride: LPS from 6 pg?ml21 to 10 mg?ml21 (Sigma); and TLR7
agonist: imiquimod from 50 pg?ml21 to 100 mg?ml21 (Sigma).
Plates were incubated for 20 h at 37uC, 5% CO2 in a humidified
environment (Thermoline Scientific, Australia).
For non-TLR stimulation of inflammatory pathways, mono-
sodium urate (MSU) crystals (suspended in phosphate buffered
saline) (Sigma) primed with a low concentration of LPS (13 pg/
mL) were used to stimulate the isolated PBMCs. The concentra-
tion of MSU crystals used ranged from 50 pg?ml21 to 10 mg?ml21.
MSU crystals are known activators of NALP3 or cryopyrin [25].
NALP3 consists of a protein complex that regulates the activity of
caspase-1 which then cleaves pro IL-1b to IL-1b. However to
respond to MSU crystals PBMCs require priming with pro-IL-1b
hence we used a low concentration of LPS (TLR4 ligand)
(13 pg?ml21). Our data show that the concentration selected for
LPS alone cause minimal release of IL-1b.
Increased TLR Responsiveness in Pain Patients
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IL-1b assay
IL-1b levels were determined by a commercially available
ELISA (IL-1b ELISA; BD Bioscience, Australia) according to the
manufacturer’s instructions. The absorbance was quantified on a
BMG Polarstar microplate reader (BMG Labtechnologies, Offen-
burg, Germany) at 450 nm with absorbance at 570 nm subtracted
as per manufacturer’s instructions. The manufacturer’s limit of
quantification of 0.8 pg?ml21 was used.
Statistical analysis
Graphpad Prism 5.0 (GraphPad Software; San Diego, CA) was
used for all statistical analysis and fitting of concentration-response
curves. The Kruskal-Wallis test was used to assess the cold pain
endurance scores. Student’s t-test was used to calculate the
difference between duration of chronic pain. The haematology
data was normalized by log transformation and analyzed with one-
way ANOVA. Age and the comparison between IL-1b expressions
with the three groups at the unstimulated level were analyzed
using one-way ANOVA. The concentration curves for TLR2,
TLR7 agonists and MSU crystals were assessed using a sigmoidal
concentration response equation. Assessments were first conducted
to determine the type of model that best described the data using
F-tests. In this case either 3 or 4 parameter sigmoidal concentra-
tion response curves were tested. In all cases except the biphasic
TLR4 response described below a 3 parameter model was found
to describe the data the best. The bottom responses were fixed at a
value of 0 but other parameters were allowed to vary. For TLR4 a
modified biphasic sigmoidal equation was used (Y= (YMin +
(YMax-YMin)/(1+10ˆ((LogEC50-X)*HillSlope)))+(YMin2 +
(YMax2-YMin2)/(1+10ˆ((LogEC502-X)*HillSlope2)))). The F-
tests were used to ask the question of whether the best fit curves
with the selected parameters (Emax, Emin and EC50) differ so that
group differences could be identify in the IL-1b expressed by
PBMCs post TLR agonist/ MSU crystals stimulation. All
significance was set at P,0.05.
Results
Demographic data
Basic demographics are listed in Table 1. Eleven chronic pain
sufferers on opioids (referred to as CP+O group) (7 female, 4 male,
(min-max) 33–65 years old; mean age 53), eight chronic pain
sufferers not on opioids (referred to as CP group)(6 female, 2 male,
36–65 years old; mean age 52) and eleven pain-free participants (7
female, 4 male; 36–61 years old; mean age 51) took part in the
study. Additional information of all chronic pain participants can
be found in Table S1. The average duration of pain in the CP+O
group was 10 years (min-max; 2–28) and for CP group was 4 years
(1–10) (P=0.08). The mean daily dose (oral morphine equivalent)
taken by CP+O was (mean 6 SEM) 85615 mg and 64% were
also on other pain modifying medications such as pregabalin and
amitriptyline. Thirty-eight percent of the CP group was on oral
analgesics such as ibuprofen and gabapentin and 50% only took
oral analgesics when required.
Cold pain endurance score
The cold pain endurance score obtained from the average of
two testing sessions for CP+O group was: (median (interquartile
range)) 28 (24–144) s, CP group was 32 (17–105) s and pain-free
was 47 (28–106) s. There were no significant differences between
either chronic pain group compared with pain-free participants
(NS; P=0.8).
Haematology
There were no differences in absolute or relative white cell
subtype counts (total white cell count, neutrophils, lymphocytes,
monocytes, eosinophils and basophils) between the groups.
In vitro stimulation with TLR agonists
The basal level (unstimulated) of IL-1b expression was the same
for all three groups: (Mean 6 SEM) CP+O group:
160.2 pg?ml21, CP group: 0.960.2 pg?ml21 and for pain-free
controls: 160.2 pg?ml21 (NS, P=0.9).
(A) TLR2 agonist: Pam3CSK4. The observed concentra-
tion-response curves were mono-phasic, with the pain-free group
appearing almost non-responsive to the TLR2 agonist
Pam3CSK4. However, Pam3CSK4 induced significant concen-
tration-dependent increases in IL-1b release in both pain groups
with the CP+O group being the most responsive. The clear
separation between the three groups resulted in an overall
significant group effect in response to Pam3CSK4 (F6, 277 = 15,
P,0.0001; see Figure 1). These differences were also reflected in
significantly different EC50 values: CP+O, 16 ng?ml21 (95%
confidence interval: 4 to 69 ng?ml21); CP, 49 ng?ml21 (95% CI:
12 to 210 ng?ml21); and PF, 53 ng ml21 (95% CI: 10 to
282 ng?ml21). The Emax estimates were also significantly different
with CP+O 827 pg?ml21 (95% CI: 622 to 1031 pg?ml21); CP,
584 pg?ml21 (95% CI: 401 to 766 pg?ml21); and PF 108 pg ml21
(95% CI: 71 to 144 pg?ml21).
(B) TLR4 agonist: LPS. The TLR4 agonist LPS induced
significant concentration-dependent increases in IL-1b release in
all groups. The observed concentration-response curve was best
fitted to a biphasic curve, suggesting both low and high affinity
systems, combining to produce the overall concentration curve. An
increased response was observed for both chronic pain populations
when compared with the controls with the CP+O group being the
most responsive. This resulted in a significant group difference in
Table 1. Demographic summary.
Chronic pain + Opioids Chronic pain – Opioids Control P
Gender (M/F) 4/7 2/6 4/7 -
Age (Years) 5363 5264 5163 0.89
Oral morphine equivalent
dose (per day) (mg)
85615 None - -
Duration of chronic pain
(Years)
1063 461 None 0.08
Data were collected from medical and family history. Data are expressed as mean 6 S.E.M. One-way ANOVA and Student’s t-test was used to determine significant
differences (P-values shown).
doi:10.1371/journal.pone.0044232.t001
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the IL-1b release concentration-response (F8, 263 = 3, P=0.002;
see Figure 2). The EC50 of CP+O was 16 ng?ml21 (95% CI: 4 to
69 ng?ml21); CP, 49 ng?ml21 (95% CI: 12 to 210 ng?ml21); PF
53 ng?ml21 (95% CI: 10 to 282 ng?ml21). The Emax were
827 pg?ml21 (95% CI: 622 to 1031 pg?ml21) for CP+O,
584 pg?ml21 (95% CI: 401 to 766 pg?ml21) for CP and
108 pg?ml21 (95% CI: 71 to 144 pg?ml21) for PF.
(C) TLR7 agonist: Imiquimod. The TLR7 agonist imiqui-
mod induced elevations in IL-1b release in only the CP+O group.
The observed concentration-response curve was monophasic and
due to the low amount of IL-1b expressed in response to TLR7 no
response curve could represent the CP group and the controls.
The differences were most prominent at the higher imiquimod
concentrations causing a marked increase in the IL-1b (F2,201 = 5,
Figure 1. TLR 2 agonist stimulation caused significant enhanced release of IL-1b in chronic pain patients. Isolated white cells obtained
from chronic pain sufferers on opioids (%), chronic pain sufferers not on opioids (N) and pain-free controls (m) were stimulated with a range of
Pam3CSK4 (TLR2) concentrations (13 pg?ml21 to 1 mg?ml21) to generate the response curves and resulted in significant group differences
(P,0.0001). Error bars on graphs represent standard error of the mean.
doi:10.1371/journal.pone.0044232.g001
Figure 2. TLR 4 agonist stimulation caused significant enhanced release of IL-1b in chronic pain patients. Isolated white cells obtained
from chronic pain sufferers on opioids (%), chronic pain sufferers not on opioids (N) and pain-free controls (m) were stimulated with a range of LPS
(TLR4) concentrations (6 pg?ml21 to 10 mg?ml21) to generate the response curves and resulted in significant differences (P = 0.002). Error bars on
graphs represent standard error of the mean.
doi:10.1371/journal.pone.0044232.g002
Increased TLR Responsiveness in Pain Patients
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P=0.005; see Figure 3). The EC50 for CP+O was 545 mg?ml21
(95% CI: 283 to 1048 mg?ml21); CP, 2371 mg?ml21 (95% CI:
1016 to 5535 mg?ml21); and PF, 2172 mg?ml21 (95% CI: 1345 to
3506 mg?ml21) for PF.
(D) NALP3: TLR independent pathway: MSU
crystals. The MSU crystals with one concentration of LPS
(13 pg ml21) induced expression of IL-1b in all three groups (data
not shown). All groups responded with a similar expression of IL-
1b at each of the tested concentrations that resulted in no
significant group or concentration differences (group effect: P=0.2
and concentration effect: P=0.7). The range of IL-1b detected
was similar to the amount released only by LPS stimulation. For
example, at 1 mg ml21 of MSU crystals with 13 pg ml21 of LPS,
the amount of IL-1b expressed in CP+O group was (mean 6
SEM) 75627 pg?ml21 (LPS alone 13 pg ml21 was
73618 pg?ml21), CP group was 112634 pg?ml21 (LPS alone
13 pg?ml21 was 119645 pg?ml21) and by PF was
82615 pg?ml21 (LPS alone 13 pg?ml21 was 35618 pg?ml21).
Discussion
The current study, to the best of the authors’ knowledge, is the
first to examine the IL-1b expression responsiveness of isolated
PBMCs collected from chronic pain sufferers (on and not on
opioid treatments) following TLR agonist stimulation. Although
basal levels of IL-1b did not differ between groups, after TLR
agonist stimulation significant group differences were detected in
the IL-1b expression levels. The response appears to be selective
for TLR pathways as there was no response found in all 3
populations after MSU crystals stimulation, (an inflammasome
activator). These findings supported both our hypotheses of
increased TLR responsiveness in pain patients and further
increases in TLR responsiveness in pain patients on opioids.
The general technique of in vitro stimulation of human PBMCs
with TLR agonists followed by quantification of cytokine
expression is not novel. This approach can be used to identify a
patient’s immunologic ‘‘signature’’ [26] and to understand the
TLR signaling pathway. Studies to evaluate TLR responsiveness
in chronic pain patients have been limited. Our study is the first to
show enhanced TLR responsiveness in PBMCs collected from
chronic pain patients when compared with controls. Previous
studies have demonstrated enhanced pro-inflammatory cytokine
release from TLR agonist stimulation in PBMCs from patients
with rheumatoid arthritis [27,28], primary biliary cirrhosis [29],
inflammatory bowel diseases [30], chronic fatigue [26] and
immunosuppressed patients with rheumatoid arthritis [31]. These
conditions with the exception chronic fatigue, are defined by
significant clinical inflammation and hence these findings are not
surprising. We took care to exclude patients with clinical
inflammation, suggesting that our findings are related to the pain
state. The further enhanced sensitivity in patients taking opioids
supports this. From the above studies, enhanced TLR-induced
release of pro-inflammatory cytokines by PBMCs indicates a
possible dysregulation in the innate immune system.
The increased responsiveness to TLR agonists could be
attributable to the chronic pain patient’s PBMC TLR system
having been ‘‘primed’’ [32] following previous exposure of
endogenous TLR ligands such as heat shock proteins [33] or
HMGB-1 [34] which may be produced after a nerve injury. Such
priming events are known to occur following painful insults. For
example increased TLR2 mRNA [35], TLR4 mRNA and pro-
inflammatory cytokine expression were found in murine models
after L5 spinal nerve transection and sciatic nerve ligation [4,36].
Interestingly, these changes in immune responsiveness are not
limited to the CNS with a recent report of increased peripheral
immune cell activity in a neuropathic pain model in mice [37]. It is
therefore possible that the increased PBMC responsiveness
observed in the chronic pain groups may be a result of up
regulation of the expression of the TLR pathways. In addition, the
different responsiveness between the TLR2 and TLR4 agonists
Figure 3. TLR 7 agonist stimulation allowed the differentiation between chronic pain patients and pain-free participants. Isolated
white cells obtained from chronic pain sufferers on opioids (%), chronic pain sufferers not on opioids (N) and pain-free controls (m) were stimulated
with a range of imiquimod (TLR7) concentrations (50 pg?ml21 to 100 mg?ml21) to generate the response curves and resulted in group differences
(P = 0.0048). Error bars on graphs represent standard error of the mean.
doi:10.1371/journal.pone.0044232.g003
Increased TLR Responsiveness in Pain Patients
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could be attributed to the availability of the TLR4 accessory
protein known as myeloid differentiation factor 2 (MD-2). LPS has
to be captured by the LPS-binding protein then delivered to the
TLR4/MD-2 complex that causes dimerization of the TLR4/
MD-2 complex. In contrast, TLR2 does not need any accessory
protein to activate downstream cascades [38]. Which pathways
and the manner of alteration that lead to the changed
responsiveness are a focus of future studies by our group.
Recently, a study unexpectedly found increased TLR4 surface
expression on monocytes and enhanced pro-inflammatory cyto-
kine (IL-8 and TNF-a) release after TLR stimulation (TLR1/2
heterodimer, TLR2/6 heterodimer, TLR4 and TLR5) in patients
with autoimmune disease who were being treated with immuno-
suppressive medications, compared with patients not receiving
immunosuppressive agents [31]. The authors hypothesized
reduced TLR4 function as an explanation of increased infection
associated with immunosuppressive therapy for autoimmune
disease. The increased release of IL-8 and TNF-a after TLR
stimulation was suggested to be as a result of altered TLR
intracellular signaling because the surface expression of TLR1 and
TLR2 did not differ from controls but the production of cytokines
were enhanced. The innate immune system was concluded to be
dysregulated and not simply suppressed. This finding parallels our
study, despite differences in patient population, cell type and
outcomes, where we observed enhanced immune response in
patients receiving opioids despite opioid medications generally
being regarded as being immunosuppressive [39] (see below).
Chronic morphine exposure is believed to cause immunosup-
pression as increased susceptibility to both bacterial and viral
infections have been reported in drug users [39]. After morphine
exposure, inhibition of the immune system, such as reduced
monocyte function have been reported in humans [40] and
decreased T-cell proliferation and NK cell function have been
reported in rodents [41]. However the evidence is not all clearly in
favor of immunosuppression, as hydrocodone and oxycodone were
found to have no immunosuppressant properties with no effect on
lymphocyte proliferation and natural killer activity found) [42].
Hence the concept of Dunne et al [31] of ‘‘dysregulation’’ may be
more appropriate to the effects of opioids than simple concepts of
enhanced or reduced immune activity. Such terms of enhanced or
reduced immune activity fail to capture the complex interactions
occurring within the immune system in which one part of the
system may show increased activity while another part of action of
the system is reduced.
A note of caution is needed with the assumption that the
increased response in the CP+O group are causally related to the
drugs using a cross sectional design. The CP+O group differed
from the CP group by higher pain scores and duration of pain. It
might seem paradoxical that patients on opioids have more pain,
but since opioid use is recommended to be restricted to those with
severe pain [43,44], and as the drugs have only modest efficacy
[43,44] this finding is not surprising. Therefore, opioid use may be
an indicator for more severe pain or pain of longer duration and
these differences may be confounders in the interpretation. In
future studies, controlling for pain intensity and duration between
the groups might be interesting and would be important to
examine in prospective longitudinal rather than cross-sectional
study designs.
No group differences were found in the basal level of IL-1b
release by PBMCs. This result is not surprising as basal level of
cytokines have yielded inconsistent findings in other patient
populations such as in rheumatoid arthritis patients. One study
reported the basal level to be the same as controls [28] whilst
another study found lower cytokine levels in rheumatoid arthritis
patients compared to controls [27]. This could be due to the very
low circulating cytokine levels but difference in sensitivity of the
system may only be revealed after stimulation.
There is clear heterogeneity in inter-laboratory reporting of the
sensitivity of PBMCs to LPS. At 1 ng/mL of LPS, the IL-1b
released from PBMCs in the control group in our study (950 pg/
mL) was higher than previous reports (600 pg/(56105/ml) [26].
Higher concentrations of LPS (1 mg/mL) produced lower amounts
of IL-1b (2008 pg/mL) compared to other studies (5000 pg/mL)
[45]. The differences could be attributed to the lack of a standard
operating procedure and specific experimental conditions in the
investigation of cytokine release from PBMCs. Other differences in
the following will also influence the outcome: the serotype of TLR
agonists used (e.g LPS), cell population used (mixed populations of
cells versus monocytes only), method of PBMC isolation, cell
concentration used and apparatus used for cytokine measurements
(bead assay, multiplex ELISA and standard ELISA kits). No
studies have investigated the TLR responsiveness of PBMCs from
chronic pain patients. One key difference between our study and
the bulk of the literature in the area is that we determined
extensive concentration-response curves whereas in most other
studies only a single concentration of agonist was used. Such single
point determinations may miss the complexity of response, like the
biphasic response we observed to LPS which has not been
reported previously.
Biphasic cytokine responses (IL-8) have been reported following
LPS stimulation in whole blood [46]. However, in this study the
secondary wave observed was due to the effect of time (first wave
was from 6–12 hours and the secondary wave was from 12–
24 hours) instead of concentration of LPS (as was observed in the
current study). The secondary wave was attributed to the LPS-
induced release of TNF and IL-1 as demonstrated with the
disappearance of the wave with the use of anti-TNF and anti-IL-1
neutralizing antibodies. In the current study the biphasic nature of
the IL-1 response may have arisen from the activation of two
systems (possibly in two cell types) that are characterized as high
affinity but low capacity, verses lower affinity but higher capacity.
This response characteristic may not have been examined before
as most studies usually only employ one high concentration of
agonist.
The specificity of the TLR agonists response was tested with the
use of the non-TLR signaling stimulus, monosodium urate
monohydrate (MSU) crystals [47]. MSU crystals are reported to
be an inflammasome activator and cause the conversions of
procaspase-1 to active caspase 1 allowing pro-IL-1b can be
cleaved to active IL-1b via the NALP3 inflammasome [48]. No
detectable IL-1b from collected PBMCs were found with pure
MSU crystals. Therefore, a low concentration of LPS (second
stimulus) was added with MSU crystal so the synergistic activation
could be measured. However, no group differences were detected
between the 3 groups. Hence it confirms our finding of the
increased responsiveness in pain patients may be TLR-specific and
not related to other pathway such as the NALP3 inflammasome.
Previously, our group found a strong correlation (Pearson r
= 0.9) between morphine-enhanced concanavalin A proliferation
(in isolated PBMCs) with cold pain endurance score in a healthy
voluntary population[49]. Therefore we wished to investigate
whether cold pain endurance could be correlated with TLR
agonist induced IL-1b levels in the PBMCs collected in the current
experiment. However no group differences were found with the
cold pain endurance scores and no correlation was found with the
TLR agonists.
Some limitations of this study are: (1) the small sample size and
heterogeneity of pain diagnosis and severity. The heterogeneity
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was deliberate as we hypothesized that it was the chronic pain
process per se and not the underlying diagnosis that was associated
with increased immune responsiveness. In future studies of larger
sample size, selecting a range of clearly defined pathologies and
controlling for pain severity would be useful. (2) Potential
confounding effects of concomitant depression and changes in
the in the hypothalamic-pituitary-adrenal axis status were not
studied, but in future work this would be appropriate as depression
may be associated with changes in glial activity [50]. (3) Only one
pro-inflammatory cytokine was measured and IL-1b was chosen as
it plays a pivotal role in chronic pain. Future studies should
examine a broader range of cytokines and chemokines.
In summary, TLR agonists (TLR2, TLR4, and TLR7) were
found to cause elevation in IL-1b release that could significantly
differentiate from chronic pain sufferers on opioids, chronic pain
sufferers not on opioids and pain-free participants. This study is
the first in providing evidence in human cells that TLRs are more
responsive in chronic pain sufferers. As we were able to
significantly differentiate three groups on the basis of their IL-1b
output, it appears this response of in vitro stimulation of isolated
immune cells with TLR agonists may serve to be a potential test
for identifying biomarkers for chronic pain from readily accessible
peripheral blood samples.
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